ATAI Life Sciences NV

ATAI Life Sciences NV

Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.59
  • Today's Change-0.002 / -0.11%
  • Shares traded824.39k
  • 1 Year change-70.26%
  • Beta--
Data delayed at least 15 minutes, as of Mar 30 2023 14:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.

  • Revenue in USD (TTM)232.00k
  • Net income in USD-152.39m
  • Incorporated2020
  • Employees119.00
  • Location
    ATAI Life Sciences NVWallstrasse 16Berlin 10179GermanyDEU
  • Phone+49 8 921539035
  • Fax+49 89 215390351
  • Websitehttps://atai.life/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
MeiraGTx Holdings PLC15.92m-129.62m255.98m343.00--2.17--16.08-2.87-2.870.35572.430.0499--0.728346,414.00-40.61-31.71-53.10-39.00-----814.16-490.79---8.650.3763---57.77---62.91--33.67--
Immuneering Corp316.96k-50.51m256.96m73.00--2.34--810.70-1.91-1.910.0124.160.0022--2.454,341.92-34.95---36.69--50.11---15,936.89------0.00---84.76---50.63------
Precigen Inc26.91m-79.78m257.24m209.00--1.68--9.56-0.39790.14080.13420.60660.093520.6822.50128,751.20-27.71-35.54-34.49-41.9576.4450.38-296.47-218.811.50-12.910.255--88.61-34.2828.00---39.53--
Thorne HealthTech Inc219.02m6.40m258.39m496.0040.231.9825.671.180.12160.12164.162.461.142.1022.27441,568.402.29--2.86--52.66--2.01--1.3343.150.0266--33.80--211.55------
Adicet Bio Inc24.99m-69.79m259.88m132.00--0.889--10.40-1.69-1.690.58686.810.0746--270.16189,318.20-20.84-32.92-22.03-35.87-----279.28-548.85----0.00--156.83---12.57--228.31--
Rani Therapeutics Holdings Inc0.00-30.59m259.91m163.00--7.05-----0.6201-0.62010.000.74590.00----0.00-54.55---111.65--------------0.2826---100.00---267.16------
ATAI Life Sciences NV232.00k-152.39m263.96m119.00--1.01--1,137.74-0.9779-0.97790.00151.570.0006--0.0281,949.58-39.30---42.55-------60,953.02------0.0538---98.86--9.19------
Pharvaris NV0.00-53.65m265.06m34.00--1.32-----1.80-1.800.005.940.00----0.00-23.22---24.69--------------0.0011-------64.44------
Acrivon Therapeutics Inc-100.00bn-100.00bn265.45m39.00--------------2.42----------------------------0.00-------206.13------
P3 Health Partners Inc969.12m-254.88m265.53m500.00--3.39--0.274-6.13-6.1323.310.32121.33--15.051,938,240.00-157.06---1,366.05---1.96---118.44-----49.120.0707--31.27---280.97------
Organogenesis Holdings Inc450.89m15.53m266.29m1.03k17.311.0010.140.59060.11730.11733.432.,760.203.481.614.222.0376.7173.633.441.412.6412.230.21040.00-3.67---83.63------
Outlook Therapeutics Inc0.00-70.25m269.50m17.00--17.10-----0.3165-0.31650.000.06140.00----0.00-99.39-205.52-132.13-2,965.91-------1,950.13---18.290.6689-------24.24------
PepGen Inc0.00-69.10m270.35m45.00--1.51-----3.01-
Codexis, Inc.138.59m-33.59m270.38m248.00--1.86--1.95-0.5138-0.51382.122.200.55823.853.53558,834.70-13.52-11.99-16.21-14.1372.5676.84-24.24-23.043.28--0.00--32.3022.61-57.86--53.18--
Atea Pharmaceuticals Inc0.00-115.91m270.86m70.00--0.4226-----1.39-1.390.007.690.00----0.00-16.10---16.99--------------0.00---100.00---195.64------
Data as of Mar 30 2023. Currency figures normalised to ATAI Life Sciences NV's reporting currency: US Dollar USD

Institutional shareholders

10.08%Per cent of shares held by top holders
HolderShares% Held
ARK Investment Management LLCas of 31 Dec 20225.66m3.41%
Suvretta Capital Management LLCas of 31 Dec 20221.64m0.99%
Morgan Stanley Investment Management, Inc.as of 31 Dec 20221.58m0.95%
BlackRock Fund Advisorsas of 31 Dec 20221.43m0.86%
Cerity Partners LLCas of 31 Dec 20221.34m0.81%
Rubric Capital Management LPas of 31 Dec 20221.32m0.80%
Millennium Management LLCas of 31 Dec 20221.24m0.75%
Two Sigma Investments LPas of 31 Dec 2022974.59k0.59%
Morgan Stanley & Co. LLCas of 31 Dec 2022797.38k0.48%
Medical Strategy GmbHas of 30 Nov 2022747.80k0.45%
More ▼
Data from 30 Nov 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.